Project Grant R01GM163329
- The National Institute of General Medical Sciences awarded Arizona State University $2,081,661 on August 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop plasmonic and evanescent scattering microscopy technologies for label-free functional imaging of single molecular and cellular activities. The recipient will advance optical detection methods that measure intrinsic molecular and cellular optical properties without fluorescent or radioactive...
- The National Institute of General Medical Sciences awarded Arizona State University $940,578 on August 6, 2026, to support the continued operation and expansion of DNASU, an academic nonprofit plasmid biorepository, through the Biomedical Research and Research Training program (CFDA 93.859). DNASU maintains a collection of over 585,000 unique plasmids from 1,269 organisms, including complete genome collections and the first complete human plasmid set. The repository acquires plasmids through...
- The National Institute of General Medical Sciences awarded Arizona State University $378,995 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to decode the toxicity-efficacy paradox in gene and nucleic acid therapies. Over five years through August 31, 2031, the funded research will generate an integrated atlas of escape-induced toxicities using phosphoproteomics, transcriptomics, and mediator profiling to map how endosomal escape location and...
- The National Institute of General Medical Sciences awarded Arizona State University $300,000 on August 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate synthetic microbial communities and their ecosystem dynamics. The project develops and characterizes synthetic two-component and higher-order E. coli microbial communities with diverse inter-strain interaction topologies, coupling bacterial toxin-antitoxin systems with quorum sensing to create...
- Federal Project Grant Award Summary Arizona State University received a $413,036 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2027. The award supports the development of a novel single-molecule glycosaminoglycan (GAG) sequencing method using fluorophore-labeled lysosomal enzymes. Glycosaminoglycans are large, linear, sulfated...
- The National Institute of General Medical Sciences awarded The Salk Institute for Biological Studies $515,625 on May 13, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on the establishment and modulation of DNA methylation patterns during plant development. The work investigates how DNA methylation patterns are generated, regulated, and inherited, with focus on reproductive tissues in Arabidopsis thaliana. The research aims to identify factors...
- The National Institute of Allergy and Infectious Diseases awarded Arizona State University $429,997 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer inducible morphotype switching control in Mycobacterium abscessus for investigating infection outcomes and discovering pathophysiological-targeted treatments. The project leverages CRISPR interference (CRISPRi) and anhydrotetracycline-inducible tetr-regulated promoter-operator systems to create...
- The National Science Foundation Division of Molecular and Cellular Biosciences awarded Arizona State University $593,493 on September 1, 2026, to investigate the molecular mechanisms governing microRNA strand selection in Caenorhabditis elegans. The award operates under the Biological Sciences program (CFDA 47.074). The research will establish the first comprehensive mechanistic framework explaining how microRNA strand selection is determined in living organisms, using the roundworm model system...
- The National Institute of General Medical Sciences awarded the University of New England $390,500 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to probe cell signaling complexity in wound healing using engineered protein materials. The recipient will investigate how a protein's molecular environment influences its function and how information flows through protein-ligand interactions using engineered proteins and protein-based materials. The work...
- The National Institute of General Medical Sciences (NIGMS) awarded the University of Arizona $410,775 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to advance synthetic bacterial adhesion tools and engineer multicellular bacterial consortia for health-relevant applications. The research focuses on developing novel synthetic cell-cell adhesion features through protein engineering, creating new synthetic genetic circuits that enable controlled...
The National Institute of General Medical Sciences awarded $343,351 to Arizona State University on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate plasmid DNA methylation in tissue repair. The research examines the delivery of unmethylated plasmid DNA (uPDNA) possessing differential prokaryotic methylation content to skin for transgene expression and tissue repair applications. Preliminary findings demonstrate that intradermal and subcutaneous delivery of uPDNA achieved high efficacies for wound closure and functional tissue recovery in both healthy and diabetic obese mice compared to methylated plasmid DNA, by activating dysregulated immune pathways in diabetic wound healing. The funded research will employ synthetic biology approaches to engineer plasmids with differential methylation numbers and sites, investigate dose-dependent efficacy of uPDNA and methylated DNA, examine the role of prokaryotic and eukaryotic methylation, test efficacy with and without polymeric delivery vehicles, and evaluate delivery of therapeutically relevant biologic transgenes for closure of full-thickness diabetic wounds and functional and biomechanical tissue recovery in mouse models. Studies will use knockout mice, immunohistochemistry, pharmacological intervention, and laser-capture microdissection. Performance occurs in Tempe, Arizona, with a period of performance extending from September 1, 2026, through April 30, 2030. Arizona State University's Office of Research and Sponsored Projects Administration administers the award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $343.4k | 8/17/26 |